$1.18
2.61% today
Nasdaq, Sep 24, 07:17 pm CET
ISIN
US17322U2078
Symbol
CTXR

Citius Pharmaceuticals Inc Stock price

$1.15
-0.11 8.73% 1M
-0.40 25.81% 6M
-2.85 71.25% YTD
-12.62 91.65% 1Y
-28.35 96.10% 3Y
-24.60 95.53% 5Y
-636.35 99.82% 10Y
-373.85 99.69% 20Y
Nasdaq, Closing price Tue, Sep 23 2025
-0.01 0.86%
ISIN
US17322U2078
Symbol
CTXR
Industry

Key metrics

Basic
Market capitalization
$19.6m
Enterprise Value
$14.5m
Net debt
positive
Cash
$6.1m
Shares outstanding
14.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 2.5
EV/Sales
- | 1.8
EV/FCF
negative
P/B
0.3
Financial Health
Equity Ratio
60.1%
Return on Equity
-57.4%
ROCE
-54.2%
ROIC
-50.6%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $7.8m
EBITDA
$-40.8m | -
EBIT
$-41.1m | $-37.3m
Net Income
$-41.0m | $-53.9m
Free Cash Flow
$-20.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-5.4% | -
EBIT
-6.4% | 11.2%
Net Income
-3.1% | -34.1%
Free Cash Flow
29.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -688.7%
Free Cash Flow
-
More
EPS
$-3.7
FCF per Share
$-1.4
Short interest
4.8%
Employees
23
Rev per Employee
$0.0
Show more

Is Citius Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Citius Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Citius Pharmaceuticals Inc forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Citius Pharmaceuticals Inc forecast:

Buy
78%
Hold
22%

Financial data from Citius Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 31 31
5% 5%
-
- Research and Development Expense 10 10
12% 12%
-
-41 -41
5% 5%
-
- Depreciation and Amortization 0.36 0.36
-
-
EBIT (Operating Income) EBIT -41 -41
6% 6%
-
Net Profit -41 -41
3% 3%
-

In millions USD.

Don't miss a Thing! We will send you all news about Citius Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Citius Pharmaceuticals Inc Stock News

Neutral
PRNewsWire
14 days ago
CRANFORD, N.J. , Sept. 10, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced the closing of its previously announced registered direct offering a...
Neutral
PRNewsWire
15 days ago
CRANFORD, N.J. , Sept. 9, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it has entered into a securities purchase agreement with a singl...
Neutral
PRNewsWire
about one month ago
Proprietary model informs targeted sales and marketing strategies with feedback loop that augments precision and impact of targeting and engagement CRANFORD, N.J. , Aug. 22, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company develop...
More Citius Pharmaceuticals Inc News

Company Profile

Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of hemorrhoids. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.

Head office United States
CEO Leonard Mazur
Employees 23
Founded 2007
Website www.citiuspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today